These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 26624971)

  • 1. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
    Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
    Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
    Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
    Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ; Berry DA; DeMichele A; Carey L; Davis SE; Buxton M; Hudis C; Gray JW; Perou C; Yau C; Livasy C; Krontiras H; Montgomery L; Tripathy D; Lehman C; Liu MC; Olopade OI; Rugo HS; Carpenter JT; Dressler L; Chhieng D; Singh B; Mies C; Rabban J; Chen YY; Giri D; van 't Veer L; Hylton N
    J Clin Oncol; 2012 Sep; 30(26):3242-9. PubMed ID: 22649152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
    Lo WC; Li W; Jones EF; Newitt DC; Kornak J; Wilmes LJ; Esserman LJ; Hylton NM
    PLoS One; 2016; 11(2):e0142047. PubMed ID: 26886725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ; Berry DA; Cheang MC; Yau C; Perou CM; Carey L; DeMichele A; Gray JW; Conway-Dorsey K; Lenburg ME; Buxton MB; Davis SE; van't Veer LJ; Hudis C; Chin K; Wolf D; Krontiras H; Montgomery L; Tripathy D; Lehman C; Liu MC; Olopade OI; Rugo HS; Carpenter JT; Livasy C; Dressler L; Chhieng D; Singh B; Mies C; Rabban J; Chen YY; Giri D; Au A; Hylton N;
    Breast Cancer Res Treat; 2012 Apr; 132(3):1049-62. PubMed ID: 22198468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
    Candelaria RP; Bassett RL; Symmans WF; Ramineni M; Moulder SL; Kuerer HM; Thompson AM; Yang WT
    Oncologist; 2017 Apr; 22(4):394-401. PubMed ID: 28314842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
    Partridge SC; Gibbs JE; Lu Y; Esserman LJ; Tripathy D; Wolverton DS; Rugo HS; Hwang ES; Ewing CA; Hylton NM
    AJR Am J Roentgenol; 2005 Jun; 184(6):1774-81. PubMed ID: 15908529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
    Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
    Jafri NF; Newitt DC; Kornak J; Esserman LJ; Joe BN; Hylton NM
    J Magn Reson Imaging; 2014 Aug; 40(2):476-82. PubMed ID: 24347097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
    Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
    Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
    Symmans WF; Peintinger F; Hatzis C; Rajan R; Kuerer H; Valero V; Assad L; Poniecka A; Hennessy B; Green M; Buzdar AU; Singletary SE; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Oct; 25(28):4414-22. PubMed ID: 17785706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
    Li W; Arasu V; Newitt DC; Jones EF; Wilmes L; Gibbs J; Kornak J; Joe BN; Esserman LJ; Hylton NM;
    Tomography; 2016 Dec; 2(4):378-387. PubMed ID: 28066808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
    Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
    Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.